ACR 2025: Phase 3 Telitacicept Results in Sjögren’s Disease
Boston, September 29, 2025 Vor Bio has announced that late-breaking Phase 3 clinical data of telitacicept in primary Sjögren’s...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Boston, September 29, 2025 Vor Bio has announced that late-breaking Phase 3 clinical data of telitacicept in primary Sjögren’s...
